ProQR Therapeutics (NASDAQ:PRQR) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.
PRQR has been the subject of several other research reports. Zacks Investment Research upgraded ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research report on Thursday, August 9th. HC Wainwright reiterated a “buy” rating on shares of ProQR Therapeutics in a research report on Monday, July 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $9.00 price target on shares of ProQR Therapeutics in a research report on Monday, August 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $13.80.
PRQR opened at $17.55 on Thursday. The stock has a market capitalization of $243.73 million, a P/E ratio of -9.05 and a beta of 0.62. ProQR Therapeutics has a 12 month low of $2.75 and a 12 month high of $17.55. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.26.
ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.15. analysts anticipate that ProQR Therapeutics will post -1.35 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in ProQR Therapeutics by 519.0% in the first quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 28,025 shares in the last quarter. Franklin Street Advisors Inc. NC grew its position in ProQR Therapeutics by 50.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock worth $657,000 after acquiring an additional 30,000 shares in the last quarter. Jennison Associates LLC grew its position in ProQR Therapeutics by 1.0% in the second quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock worth $21,763,000 after acquiring an additional 30,831 shares in the last quarter. Ardsley Advisory Partners purchased a new position in ProQR Therapeutics in the second quarter worth about $365,000. Finally, Essex Investment Management Co. LLC purchased a new position in ProQR Therapeutics in the second quarter worth about $604,000. Institutional investors own 34.75% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Further Reading: Determine Your Level of Risk Tolerance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.